Fate Therapeutics, Inc. (NASDAQ:FATE) CEO J Scott Wolchko Sells 69,407 Shares


Share on StockTwits

Fate Therapeutics, Inc. (NASDAQ:FATE) CEO J Scott Wolchko sold 69,407 shares of the stock in a transaction on Monday, January 11th. The stock was sold at an average price of $116.33, for a total value of $8,074,116.31. Following the sale, the chief executive officer now owns 393,065 shares in the company, valued at approximately $45,725,251.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

J Scott Wolchko also recently made the following trade(s):

  • On Friday, January 8th, J Scott Wolchko sold 60,820 shares of Fate Therapeutics stock. The stock was sold at an average price of $117.10, for a total value of $7,122,022.00.
  • On Friday, November 13th, J Scott Wolchko sold 60,000 shares of Fate Therapeutics stock. The stock was sold at an average price of $51.87, for a total value of $3,112,200.00.

FATE opened at $113.29 on Thursday. The business’s fifty day simple moving average is $88.49 and its 200 day simple moving average is $51.78. Fate Therapeutics, Inc. has a 52 week low of $16.75 and a 52 week high of $118.79. The stock has a market cap of $9.88 billion, a PE ratio of -61.57 and a beta of 1.84.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.39). Fate Therapeutics had a negative net margin of 810.13% and a negative return on equity of 35.51%. The company had revenue of $7.56 million for the quarter, compared to the consensus estimate of $7.49 million. During the same period last year, the business posted ($0.40) earnings per share. The firm’s quarterly revenue was up 211.2% compared to the same quarter last year. As a group, equities research analysts predict that Fate Therapeutics, Inc. will post -1.53 EPS for the current year.

Large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Fate Therapeutics by 9.1% during the third quarter. The Manufacturers Life Insurance Company now owns 40,923 shares of the biopharmaceutical company’s stock valued at $1,636,000 after purchasing an additional 3,404 shares during the last quarter. Strs Ohio lifted its holdings in shares of Fate Therapeutics by 92.6% during the third quarter. Strs Ohio now owns 5,200 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 2,500 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Fate Therapeutics by 15.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 444,272 shares of the biopharmaceutical company’s stock valued at $15,243,000 after purchasing an additional 58,866 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Fate Therapeutics by 36.6% during the second quarter. Nuveen Asset Management LLC now owns 530,980 shares of the biopharmaceutical company’s stock valued at $18,218,000 after purchasing an additional 142,207 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in shares of Fate Therapeutics during the second quarter valued at approximately $354,000. 97.45% of the stock is currently owned by hedge funds and other institutional investors.

FATE has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price objective on Fate Therapeutics from $61.00 to $84.00 and gave the stock an “overweight” rating in a research report on Monday, December 7th. BidaskClub upgraded Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 14th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price objective on Fate Therapeutics from $63.00 to $76.00 in a research report on Monday, December 7th. BMO Capital Markets increased their price objective on Fate Therapeutics from $43.00 to $57.00 and gave the stock a “market perform” rating in a research report on Monday, December 7th. Finally, Zacks Investment Research upgraded Fate Therapeutics from a “sell” rating to a “hold” rating and set a $42.00 price objective on the stock in a research report on Thursday, November 19th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $66.68.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors.

Further Reading: What is the Dividend Aristocrat Index?

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.